ClinicalTrials.gg
TerminatedNCT01958593Updated Jun 5, 2025Results posted

Randomized, Double-blind, Controlled of MDMA-assisted Psychotherapy in 12 Subjects With PTSD

A Phase 2 interventional study of Placebo and Midomafetamine HCl in Posttraumatic Stress Disorder, sponsored by Lykos Therapeutics. Terminated at 1 site in Canada. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2025-06-05.

Sponsored by Lykos Therapeutics (part of Resilient Pharmaceuticals) · Phase 2, Interventional, and Prevention

Why this study was terminated
This pilot study was terminated early by sponsor due to insufficient rate of accrual.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
6
Allocation
Randomized
Ages
21 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 38 studies testing N-Methyl-3,4-methylenedioxyamphetamine in Stress Disorders, Post-Traumatic — 11 open to participants now, 12 under way, 1 of them phase 3. N-Methyl-3,4-methylenedioxyamphetamine · Stress Disorders, Post-Traumatic.

Enrollment
30th of 38
6 · median 25
Started
2014
the only one that year
Phase 2
28 of 38
10 open now
Registered
8th of 38
by date
Lead sponsor
16 of 38
Lykos Therapeutics

Among the 38 studies testing N-Methyl-3,4-methylenedioxyamphetamine in Stress Disorders, Post-Traumatic, this one is the 30th largest by enrollment, is the only one that started in 2014, is one of 28 in phase 2, and was the 8th registered.

Stress Disorders, Post-Traumatic

2,688 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 606 are open to participants now.

Browse Stress Disorders, Post-Traumatic studies →

Open to participants now

11 of the 38 studies testing N-Methyl-3,4-methylenedioxyamphetamine in Stress Disorders, Post-Traumatic are open now, in 3 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About N-Methyl-3,4-methylenedioxyamphetamine

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 417 Stress Disorders, Post-Traumatic studies recruiting now, 187 (45%) set no upper age limit and 204 (49%) stop at 75 or younger; 63 take children under 18; 89 take healthy volunteers.

This study: 21 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies testing N-Methyl-3,4-methylenedioxyamphetamine in Stress Disorders, Post-Traumatic, or all of them as a file.
02

Study summary

The goal of this clinical trial is to compare full dose MDMA-assisted therapy to placebo with therapy in participants with chronic, treatment-resistant PTSD. The main question it aims to answer is: Does MDMA-assisted therapy versus placebo with therapy reduce PTSD symptoms?

Participants will receive either MDMA-assisted therapy or placebo with therapy during two blinded experimental sessions spaced three to five weeks apart. During experimental sessions, participants receive an initial dose of 125 mg of MDMA HCl, or placebo, followed by a dose of 62.5 mg of MDMA HCl, or placebo. During this treatment period, participants will also undergo non-drug preparatory therapy sessions and non-drug integration sessions.

Researchers will compare PTSD symptoms in the MDMA-assisted therapy group to the placebo with therapy group to see if there is a reduction in symptoms after the treatment period. Safety measures will also be assessed between groups.

Read the detailed description

This randomized, double-blind, placebo-controlled clinical study will assess the safety and efficacy of MDMA-assisted therapy in treating chronic, treatment-resistant PTSD. In Stage 1, participants will be randomized to either MDMA-assisted therapy or placebo with therapy during two blinded experimental sessions, spaced three to five weeks apart. During experimental sessions, participants receive an initial dose of 125 mg of MDMA HCl, or placebo, followed by a dose of 62.5 mg of MDMA HCl, or placebo. During this treatment period, participants will also undergo non-drug preparatory therapy sessions and non-drug integration sessions. After this treatment period, participants will complete the primary endpoint assessment and the study will become unblinded.

Participants who were assigned to receive MDMA-assisted therapy will receive a third session of MDMA-assisted therapy that is open-label and participants assigned to receive placebo with therapy will have the option to enter Stage 2. Stage 2 will explore the optimal therapeutic dose of MDMA in a clinical titration dosing strategy. Participants will receive MDMA-assisted with an initial dose of 100 mg followed by a dose of 50 mg of MDMA HCl for the first experimental session. In the second and third experimental sessions, participants will have the option to increase the dose to an initial dose of 125 mg followed by a dose of 62.5 mg.

A blinded independent rater will assess PTSD symptoms via the CAPS-IV as well as other secondary outcome measures and safety measures.

03

Conditions studied

  • Posttraumatic Stress Disorder

Keywords

  • PTSD
  • Posttraumatic stress disorder
  • MDMA
  • psychotherapy
  • therapy
04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with moderate to severe PTSD;
  • Have chronic PTSD, defined as persisting for longer than 6 months;
  • Have treatment-resistant PTSD, meaning unable to achieve remission despite previous therapy or medication or discontinued treatment due to inability to tolerate previous therapy or medication;
  • Are willing to refrain from taking any psychiatric medications during the study period;
  • Willing to remain overnight at the study site;
  • Agree to have transportation home after experimental sessions;
  • Are willing to be contacted via telephone for all necessary telephone contacts;
  • Must have a negative pregnancy test if able to bear children, and agree to use an effective form of ;
  • Are proficient in speaking and reading English;
  • Agree not to participate in any other interventional clinical trials during the duration of this study.

Exclusion criteria

Exclusion Criteria:

  • Are pregnant or nursing, or if of child bearing potential, are not practicing an effective means of ;
  • Weigh less than 48 kg;
  • Are unable to give adequate ;
  • Upon review of past and current drugs/medication must not be on or have taken a medication that is exclusionary;
  • Have used "Ecstasy" (illicit drug preparations purported to contain MDMA) more than five times in the last 10 years or at least once within six months of enrollment;
  • Upon review of medical or psychiatric history must not have any current or past diagnosis that would be considered a risk to participation in the study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
6 participants (actual)

Study arms

  • Placebo comparator
    Placebo with therapy

    Participants will receive placebo with therapy during each of two experimental sessions.

    Drug: Placebo · Behavioral: Psychotherapy

  • Experimental
    MDMA-assisted therapy

    Participants will receive MDMA (initial dose of 125 mg midomafetamine HCl followed by a supplemental dose of 62.5 mg midomafetamine HCl) with therapy during each of two experimental sessions.

    Drug: Midomafetamine HCl · Behavioral: Psychotherapy

Interventions

  • DrugPlacebo

    Placebo with therapy administered in two blinded experimental sessions. Participants in this group in Stage 1 may take part in Stage 2.

    Also known as: Inactive placebo

  • Participants will receive MDMA-assisted therapy during two blinded experimental sessions. After unblinding, may receive a third session of open-label MDMA-assisted therapy.

    Also known as: MDMA HCl, 3,4-methylenedioxymethamphetamine, midomafetamine, MDMA

  • BehavioralPsychotherapy

    Psychotherapy before and after experimental sessions.

06

What researchers measure

Primary outcomes

  1. Change in Clinician-Administered PTSD Scale (CAPS-IV) Score From Baseline to Primary Endpoint

    Clinician-administered and scored assessment of PTSD symptoms via structured interview, including global symptom severity, dichotomous diagnostic score and subscale scores. The Clinician-Administered PTSD Scale for DSM-4 (CAPS-4) is a clinician administered and scored assessment of PTSD symptoms via structured interview based upon PTSD diagnosis in DSM-4. It contains symptom subscales, a CAPS-4 total severity score, and a diagnostic score. The total severity score is a sum of symptom frequency and intensity scores for the subscales B (re-experiencing), C (avoidance) and D (hypervigilance) and ranges from 0 to 136, with higher scores indicating greater severity of PTSD symptoms.

    Time frame: Baseline to Primary Endpoint (Primary Endpoint was approximately 18 weeks after Baseline and 1 month after the 2nd experimental session)

Secondary outcomes

  1. Change in PTSD Diagnostic Scale (PDS) Total Severity Score From Baseline to Primary Endpoint

    The PTSD Diagnostic Scale (PDS) is a 49 item self-report measure designed to follow DSM-IV criteria for assessing PTSD. The PDS consists of a checklist to identify potentially traumatizing events experienced by the respondent and respondents then indicate which of the experienced events has troubled them the most in the last month and rate their response to this event at the time of its occurrence. Respondents then rate the severity of 17 items representing the cardinal symptoms of PTSD experienced in the past 30 days on a scale from 0 ("not at all") to 3 ("5 or more times a week") as well as the level of impairment caused by their symptoms across nine areas of life functioning. The 17 symptom severity items are summed to create a total symptom severity score, which ranges from 0 to 51, with higher scores indicating greater symptom severity and/or frequency.

    Time frame: Baseline to Primary Endpoint (Primary Endpoint was approximately 18 weeks after Baseline and 1 month after the 2nd experimental session)

  2. Change in Beck Depression Inventory (BDI-II) Score From Baseline to Primary Endpoint

    The BDI-II is a validated 21-item self-report measure of symptoms of depression according to DSM-IV criteria. A BDI-II total score of 0-13 is considered minimal range, 14-19 is mild, 20-28 is moderate, and 29-63 is severe depressive symptoms. The scores range from 0 to 63, with higher score indicating greater severity of depressive symptoms.

    Time frame: Baseline to Primary Endpoint (Primary Endpoint was approximately 18 weeks after Baseline and 1 month after the 2nd experimental session)

  3. Change in Global Assessment of Functioning (GAF) Score From Baseline to Primary Endpoint

    The GAF Scale is a numeric scale ranging from 0 (serious risk of causing harm to the self or others) through 100 (superior function) that is used by mental health clinicians and physicians to subjectively rate the social, occupational, and psychological functioning of adults. The GAF is a reliable, validated measure of social functioning (Goldman, Skodol, and Lave, 1992). Higher scores indicate better functioning.

    Time frame: Baseline to Primary Endpoint (Primary Endpoint was approximately 18 weeks after Baseline and 1 month after the 2nd experimental session)

  4. Change in Pittsburgh Sleep Quality Index (PSQI) Score From Baseline to Primary Endpoint

    The PSQI is a self-rated questionnaire which assesses sleep quality and disturbances. It is comprised of 19 items that yield 7 component scores. Component scores are summed to create a total score. Total scores range from 0 (better) to 21 (worse), with higher scores indicating poor sleep quality.

    Time frame: Baseline to Primary Endpoint (Primary Endpoint was approximately 18 weeks after Baseline and 1 month after the 2nd experimental session)

  5. Change in Dissociation Experiences Scale II (DES-II) Total Score From Baseline to Primary Endpoint

    The DES-II is a 28-item self-report measure of dissociation, defined as a lack of normal integration of an individual's thoughts, feelings, or experiences into the stream of consciousness or memory. It is an established measure of dissociative symptoms. The scale consists of statements describing facets of dissociation. Respondents indicate how often the specific experience happens to them, from from "never" (0% of the time) to "always" (100%). The scale is scored by treating percentages as single digits and averaging to produce a total score, ranging from 0 to 100. The higher the score, the more dissociative symptoms.

    Time frame: Baseline to Primary Endpoint (Primary Endpoint was approximately 18 weeks after Baseline and 1 month after the 2nd experimental session)

  6. Change in Posttraumatic Growth Inventory (PTGI) Total Score From Baseline to Primary Endpoint

    The PTGI is a 21-item self-report measure of perceived growth or benefits occurring after a traumatic event. It contains 5 subscales: relationship to others, new possibilities, personal strength, spiritual change, and appreciation of life. Responses to each question are made on a scale of 0 (no change) to 5 (great degree of change), with higher scores indicating greater personal growth. Items are added to calculate the total PTGI score which ranges from 0 to 105, with higher scores indicative of greater growth.

    Time frame: Baseline to Primary Endpoint (Primary Endpoint was approximately 18 weeks after Baseline and 1 month after the 2nd experimental session)

07

Results

Posted Aug 2, 2021

Participant flow

Participants were recruited through printed ads, internet ads, referrals from other psychiatrists, psychotherapists or physicians, and through word of mouth.

Stage 1
Participant flow — Stage 1
MilestonePlacebo With TherapyMDMA-assisted Therapy
Started24
Completed24
Not completed00
Stage 2 Open-label Crossover
Participant flow — Stage 2 Open-label Crossover
MilestonePlacebo With TherapyMDMA-assisted Therapy
Started20
Completed20
Not completed00

Outcome measures

PrimaryChange in Clinician-Administered PTSD Scale (CAPS-IV) Score From Baseline to Primary Endpoint

Clinician-administered and scored assessment of PTSD symptoms via structured interview, including global symptom severity, dichotomous diagnostic score and subscale scores. The Clinician-Administered PTSD Scale for DSM-4 (CAPS-4) is a clinician administered and scored assessment of PTSD symptoms via structured interview based upon PTSD diagnosis in DSM-4. It contains symptom subscales, a CAPS-4 total severity score, and a diagnostic score. The total severity score is a sum of symptom frequency and intensity scores for the subscales B (re-experiencing), C (avoidance) and D (hypervigilance) and ranges from 0 to 136, with higher scores indicating greater severity of PTSD symptoms.

Time frame:
Baseline to Primary Endpoint (Primary Endpoint was approximately 18 weeks after Baseline and 1 month after the 2nd experimental session)
Reported as:
Mean · score on a scale
Change in Clinician-Administered PTSD Scale (CAPS-IV) Score From Baseline to Primary Endpoint
score on a scalePlacebo With TherapyMDMA-assisted Therapy
Change in Clinician-Administered PTSD Scale (CAPS-IV) Score From Baseline to Primary Endpoint-21.5 ± 12.02-17.3 ± 13.05
SecondaryChange in PTSD Diagnostic Scale (PDS) Total Severity Score From Baseline to Primary Endpoint

The PTSD Diagnostic Scale (PDS) is a 49 item self-report measure designed to follow DSM-IV criteria for assessing PTSD. The PDS consists of a checklist to identify potentially traumatizing events experienced by the respondent and respondents then indicate which of the experienced events has troubled them the most in the last month and rate their response to this event at the time of its occurrence. Respondents then rate the severity of 17 items representing the cardinal symptoms of PTSD experienced in the past 30 days on a scale from 0 ("not at all") to 3 ("5 or more times a week") as well as the level of impairment caused by their symptoms across nine areas of life functioning. The 17 symptom severity items are summed to create a total symptom severity score, which ranges from 0 to 51, with higher scores indicating greater symptom severity and/or frequency.

Time frame:
Baseline to Primary Endpoint (Primary Endpoint was approximately 18 weeks after Baseline and 1 month after the 2nd experimental session)
Reported as:
Mean · score on a scale
Change in PTSD Diagnostic Scale (PDS) Total Severity Score From Baseline to Primary Endpoint
score on a scalePlacebo With TherapyMDMA-assisted Therapy
Change in PTSD Diagnostic Scale (PDS) Total Severity Score From Baseline to Primary Endpoint-1.0 ± 5.66-5.3 ± 1.53
SecondaryChange in Beck Depression Inventory (BDI-II) Score From Baseline to Primary Endpoint

The BDI-II is a validated 21-item self-report measure of symptoms of depression according to DSM-IV criteria. A BDI-II total score of 0-13 is considered minimal range, 14-19 is mild, 20-28 is moderate, and 29-63 is severe depressive symptoms. The scores range from 0 to 63, with higher score indicating greater severity of depressive symptoms.

Time frame:
Baseline to Primary Endpoint (Primary Endpoint was approximately 18 weeks after Baseline and 1 month after the 2nd experimental session)
Reported as:
Mean · score on a scale
Change in Beck Depression Inventory (BDI-II) Score From Baseline to Primary Endpoint
score on a scalePlacebo With TherapyMDMA-assisted Therapy
Change in Beck Depression Inventory (BDI-II) Score From Baseline to Primary Endpoint-4.0 ± 2.832.0 ± 15.34
SecondaryChange in Global Assessment of Functioning (GAF) Score From Baseline to Primary Endpoint

The GAF Scale is a numeric scale ranging from 0 (serious risk of causing harm to the self or others) through 100 (superior function) that is used by mental health clinicians and physicians to subjectively rate the social, occupational, and psychological functioning of adults. The GAF is a reliable, validated measure of social functioning (Goldman, Skodol, and Lave, 1992). Higher scores indicate better functioning.

Time frame:
Baseline to Primary Endpoint (Primary Endpoint was approximately 18 weeks after Baseline and 1 month after the 2nd experimental session)
Reported as:
Mean · score on a scale
Change in Global Assessment of Functioning (GAF) Score From Baseline to Primary Endpoint
score on a scalePlacebo With TherapyMDMA-assisted Therapy
Change in Global Assessment of Functioning (GAF) Score From Baseline to Primary Endpoint5.0 ± 4.245.3 ± 3.86
SecondaryChange in Pittsburgh Sleep Quality Index (PSQI) Score From Baseline to Primary Endpoint

The PSQI is a self-rated questionnaire which assesses sleep quality and disturbances. It is comprised of 19 items that yield 7 component scores. Component scores are summed to create a total score. Total scores range from 0 (better) to 21 (worse), with higher scores indicating poor sleep quality.

Time frame:
Baseline to Primary Endpoint (Primary Endpoint was approximately 18 weeks after Baseline and 1 month after the 2nd experimental session)
Reported as:
Mean · score on a scale
Change in Pittsburgh Sleep Quality Index (PSQI) Score From Baseline to Primary Endpoint
score on a scalePlacebo With TherapyMDMA-assisted Therapy
Change in Pittsburgh Sleep Quality Index (PSQI) Score From Baseline to Primary Endpoint1.0 ± 1.41-3.5 ± 3.32
SecondaryChange in Dissociation Experiences Scale II (DES-II) Total Score From Baseline to Primary Endpoint

The DES-II is a 28-item self-report measure of dissociation, defined as a lack of normal integration of an individual's thoughts, feelings, or experiences into the stream of consciousness or memory. It is an established measure of dissociative symptoms. The scale consists of statements describing facets of dissociation. Respondents indicate how often the specific experience happens to them, from from "never" (0% of the time) to "always" (100%). The scale is scored by treating percentages as single digits and averaging to produce a total score, ranging from 0 to 100. The higher the score, the more dissociative symptoms.

Time frame:
Baseline to Primary Endpoint (Primary Endpoint was approximately 18 weeks after Baseline and 1 month after the 2nd experimental session)
Reported as:
Mean · score on a scale
Change in Dissociation Experiences Scale II (DES-II) Total Score From Baseline to Primary Endpoint
score on a scalePlacebo With TherapyMDMA-assisted Therapy
Change in Dissociation Experiences Scale II (DES-II) Total Score From Baseline to Primary Endpoint8.4 ± 3.79-4.6 ± 13.63
SecondaryChange in Posttraumatic Growth Inventory (PTGI) Total Score From Baseline to Primary Endpoint

The PTGI is a 21-item self-report measure of perceived growth or benefits occurring after a traumatic event. It contains 5 subscales: relationship to others, new possibilities, personal strength, spiritual change, and appreciation of life. Responses to each question are made on a scale of 0 (no change) to 5 (great degree of change), with higher scores indicating greater personal growth. Items are added to calculate the total PTGI score which ranges from 0 to 105, with higher scores indicative of greater growth.

Time frame:
Baseline to Primary Endpoint (Primary Endpoint was approximately 18 weeks after Baseline and 1 month after the 2nd experimental session)
Reported as:
Mean · score on a scale
Change in Posttraumatic Growth Inventory (PTGI) Total Score From Baseline to Primary Endpoint
score on a scalePlacebo With TherapyMDMA-assisted Therapy
Change in Posttraumatic Growth Inventory (PTGI) Total Score From Baseline to Primary Endpoint8.5 ± 14.85-3.7 ± 11.85

Adverse events

Collected over All AEs from baseline to the end of Stage 2 (approximately 10 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo With Therapy (Stage 1)0/2 (0%)0/2 (0%)2/2 (100%)
MDMA-assisted Therapy (Stage 1)0/4 (0%)0/4 (0%)4/4 (100%)
Placebo With Therapy (Stage 2)0/2 (0%)0/2 (0%)2/2 (100%)
SRRs: Placebo With Therapy0/2 (0%)0/2 (0%)2/2 (100%)
SRRs: MDMA-assisted Therapy0/4 (0%)0/4 (0%)4/4 (100%)
Most frequent other events
Showing 10 of 30
Most frequent other events
EventPlacebo With Therapy (Stage 1)MDMA-assisted Therapy (Stage 1)Placebo With Therapy (Stage 2)SRRs: Placebo With TherapySRRs: MDMA-assisted Therapy
FatigueGeneral disorders0/21/40/22/24/4
HeadacheNervous system disorders0/21/40/22/24/4
AnxietyPsychiatric disorders0/22/40/22/24/4
InsomniaPsychiatric disorders0/21/40/22/24/4
Difficulty ConcentratingGeneral disorders0/20/40/22/23/4
Low moodGeneral disorders0/20/40/22/23/4
Muscle TensionGeneral disorders0/20/40/22/23/4
Need More SleepGeneral disorders0/20/40/22/23/4
NauseaGastrointestinal disorders0/21/40/21/23/4
RuminationsGeneral disorders0/20/40/21/23/4

Baseline characteristics

Age, Continuous
Age, Continuous(years)Placebo With TherapyMDMA-assisted TherapyTotal
Mean44.0 ± 12.6649.6 ± 7.947.7 ± 8.82
Sex: Female, Male
Sex: Female, Male(Participants)Placebo With TherapyMDMA-assisted TherapyTotal
Female123
Male123
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo With TherapyMDMA-assisted TherapyTotal
Hispanic or Latino000
Not Hispanic or Latino246
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Placebo With TherapyMDMA-assisted TherapyTotal
Race — White235
Race — Other011
08

Study locations

1 site
  • Offices of Dr. Ingrid Pacey MBBS FRCP[C]
    Vancouver, British Columbia V6R 1N6, Canada
09

References and documents

Publications

  • Jerome L, Feduccia AA, Wang JB, Hamilton S, Yazar-Klosinski B, Emerson A, Mithoefer MC, Doblin R. Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials. Psychopharmacology (Berl). 2020 Aug;237(8):2485-2497. doi: 10.1007/s00213-020-05548-2. Epub 2020 Jun 4. PubMed 32500209 ↗
  • Feduccia AA, Jerome L, Yazar-Klosinski B, Emerson A, Mithoefer MC, Doblin R. Breakthrough for Trauma Treatment: Safety and Efficacy of MDMA-Assisted Psychotherapy Compared to Paroxetine and Sertraline. Front Psychiatry. 2019 Sep 12;10:650. doi: 10.3389/fpsyt.2019.00650. eCollection 2019. PubMed 31572236 ↗
  • Mithoefer MC, Feduccia AA, Jerome L, Mithoefer A, Wagner M, Walsh Z, Hamilton S, Yazar-Klosinski B, Emerson A, Doblin R. MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials. Psychopharmacology (Berl). 2019 Sep;236(9):2735-2745. doi: 10.1007/s00213-019-05249-5. Epub 2019 May 7. PubMed 31065731 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2014 to primary completion in Sep 2015, 10 months.

Results were first posted in Aug 2021, 5 years 10 months after primary completion. A results delay was requested in Dec 2017.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 7, 2013
First posted
Oct 9, 2013
StartActual
Oct 14, 2014
Primary completionActual
Sep 10, 2015
CompletionActual
Oct 17, 2016
Results delay requested
Dec 6, 2017
Results first posted
Aug 2, 2021
Last update
Jun 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01958593
Lead sponsor
Lykos Therapeutics
Responsible party
Sponsor
First posted
Oct 9, 2013
Start date
Oct 14, 2014
Primary completion
Sep 10, 2015
Completion
Oct 17, 2016
Results posted
Aug 2, 2021
Last update
Jun 5, 2025

Study contacts

Ingrid Pacey, MBBS FRCP[C]
principal investigator · University of Victoria
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: N-Methyl-3,4-methylenedioxyamphetamine

Start the discussion